Cargando…

Current Treatment Options in CLL

SIMPLE SUMMARY: Standard treatment for chronic lymphocytic leukemia (CLL) has experienced a dramatic change over the last years. Until recently, CLL was treated using chemotherapy in combination with anti-CD20 antibody-based immunotherapy. Depending on age and clinical condition, patients received m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bewarder, Moritz, Stilgenbauer, Stephan, Thurner, Lorenz, Kaddu-Mulindwa, Dominic
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158749/ https://www.ncbi.nlm.nih.gov/pubmed/34069354 http://dx.doi.org/10.3390/cancers13102468

Ejemplares similares

Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2022)

Protection strategy against outbreak of COVID-19 at a tertiary hematology-oncology: strengths and pitfalls
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2021)

Adjuvant Therapy of High-Risk (Stages IIC–IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis
por: Christofyllakis, Konstantinos, et al.
Publicado: (2021)

Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab
por: Kos, Igor, et al.
Publicado: (2020)

Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma
por: Bewarder, Moritz, et al.
Publicado: (2020)

IgG seroprevalence of COVID‐19 among people living with HIV or at high risk of HIV in south‐west Germany: A seroprevalence study
por: Kaddu‐Mulindwa, Dominic, et al.
Publicado: (2021)

Vitamin D Enhances Immune Effector Pathways of NK Cells Thus Providing a Mechanistic Explanation for the Increased Effectiveness of Therapeutic Monoclonal Antibodies
por: Christofyllakis, Konstantinos, et al.
Publicado: (2023)

Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential
por: Bewarder, Moritz, et al.
Publicado: (2020)

Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019
por: Lesan, Vadim, et al.
Publicado: (2021)

Advances in Lymphoma Molecular Diagnostics
por: Kos, Igor Age, et al.
Publicado: (2021)

The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells
por: Bewarder, Moritz, et al.
Publicado: (2021)

Increased B‐cell activity with consumption of activated monocytes in severe COVID‐19 patients
por: Kos, Igor, et al.
Publicado: (2021)

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2021)

PB2104: DOSE-DENSE CHEMOTHERAPY WITH R-CHOP-14 IN OLDER ADULTS AGED ≥80 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Christofyllakis, K., et al.
Publicado: (2022)

Role of Specific B-Cell Receptor Antigens in Lymphomagenesis
por: Thurner, Lorenz, et al.
Publicado: (2020)

Targeted therapy in CLL: changing the treatment paradigm
por: Schneider, Christof, et al.
Publicado: (2019)

Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2022)

Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP
por: Bewarder, Moritz, et al.
Publicado: (2023)

Renal AA amyloidosis leading to early diagnosis and treatment of takayasu arteritis: a case report and review of the literature
por: Kos, Igor, et al.
Publicado: (2020)

From Biology to Therapy: The CLL Success Story
por: Yosifov, Deyan Y., et al.
Publicado: (2019)

Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells
por: Kiefer, Maximilian, et al.
Publicado: (2022)

To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL?
por: Urbanek, Karol D., et al.
Publicado: (2022)

The riddle of lymphoma BCR-antigenes
por: Thurner, Lorenz, et al.
Publicado: (2018)

Emerging treatment options for patients with p53-pathway-deficient CLL
por: Aitken, Marisa J. L., et al.
Publicado: (2019)

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
por: Molica, Stefano, et al.
Publicado: (2023)

Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma
por: Thurner, Lorenz, et al.
Publicado: (2020)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Current Therapeutic Options in the Treatment of Rheumatoid Arthritis
por: Köhler, Birgit M., et al.
Publicado: (2019)

Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL
por: Gärtner, Kathrin, et al.
Publicado: (2019)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
por: Simon, Florian, et al.
Publicado: (2023)

Landscape of 4D Cell Interaction in Hodgkin and Non-Hodgkin Lymphomas
por: Hartmann, Sylvia, et al.
Publicado: (2021)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
por: Langerbeins, Petra, et al.
Publicado: (2023)

Survey of Brucella infection and malaria among Abattoir workers in Kampala and Mbarara Districts, Uganda
por: Nabukenya, Immaculate, et al.
Publicado: (2013)

Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options
por: Kohoutova, Darina, et al.
Publicado: (2021)

Current options for the treatment of optic neuritis
por: Pula, John H, et al.
Publicado: (2012)

Current treatment options for acanthosis nigricans
por: Patel, Nupur U, et al.
Publicado: (2018)

Chronic prostatitis: current treatment options
por: Pirola, Giacomo Maria, et al.
Publicado: (2019)

Pseudofolliculitis barbae; current treatment options
por: Ogunbiyi, Adebola
Publicado: (2019)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_65i36nmd26p6d7fofcbmik5d58